Distribution of risk markers and treatments per dataset
| . | HO65/HD4 . | MRC-IX . | TT2 . | TT3 . | APEX . | IFM-G . | Pooled . | |
|---|---|---|---|---|---|---|---|---|
| . | . | Intensive . | Nonintensive . | . | . | . | . | . |
| N | 827 | 701 | 491 | 351 | 238 | 264 | 1878 | 4750* |
| Age, median (IQR), y | 57 (51-61) | 58 (54-63) | 74 (70-77) | 57 (49-64) | 60 (53-66) | 61 (54-67) | 57 (51-61) | 57 (51-62) |
| Treatment, n | PAD (413) | CTD (351) | CTDa (257) | VTD (175) | VTD (238) | BOR (188) | VD (740) | BOR (1579)/ THAL (783) |
| Control, n | VAD (414) | CVAD (350) | MP (234) | VMD (176) | No controls | DEX (76) | VAD (1138) | BOR (1628)/ THAL (760) |
| High-dose alkylator | Yes | Yes | No | Yes | Yes | Yes | Yes | |
| EMC92, n (% positive) | † | 138 (17) | 109 (24) | 345 (19) | 238 (15) | 264 (16) | 1094 (18) | |
| UAMS17, n (% positive) | 327 (12) | 138 (9) | 109 (16) | † | 238 (14) | 264 (12) | 1076 (12) | |
| UAMS70, n (% positive) | 327 (9) | 138 (7) | 109 (10) | † | 238 (12) | 264 (8) | 1076 (9) | |
| UAMS80, n (% positive) | 327 (8) | 138 (8) | 109 (9) | 345 (9) | † | 264 (7) | 1183 (8) | |
| MRCIX6, n (% positive) | 327 (5) | † | † | 345 (7) | 238 (5) | 264 (3) | 1174 (5) | |
| IFM15, n (% positive) | 327 (25) | 138 (25) | 109 (28) | 345 (24) | 238 (24) | 1157 (25) | ||
| HM19, n (low/medium/high %) | 327 (43/49/8) | 138 (45/48/7) | 109 (39/53/8) | 345 (50/47/8) | 238 (47/47/7) | 264 (41/50/8) | 1420 (44/48/8) | |
| GPI50, n (low/medium/high %) | 327 (34/51/15) | 138 (52/41/7) | 109 (52/38/10) | 345 (63/31/7) | 238 (58/34/8) | 1159 (51/39/10) | ||
| ISS, n (1/2/3%) | 756 (38/37/25) | 636 (25/39/36) | 449 (13/41/45) | 351 (54/25/21) | 208 (50/28 21) | 202 (34/33/33) | 1475 (34/39/28) | 4074 (34/37/30) |
| t(4;14), n (% positive) | 492 (12) | 619 (12) | 434 (10) | 1635 (14) | 3180 (13) | |||
| t(11;14), n (% positive) | 437 (16) | 617 (15) | 434 (12) | 1488 (15) | ||||
| t(14;16), n (% positive) | 360 (2) | 612 (3) | 434 (3) | 456 (4) | 1862 (3) | |||
| t(14;20), n (% positive) | 255 (0) | 612 (2) | 429 (1) | 1296 (1) | ||||
| IgH split, n (% positive) | 372 (48) | 609 (44) | 429 (40) | 1410 (44) | ||||
| gain1q, n (% positive) | 344 (32) | 531 (37) | 371 (41) | 248 (47) | 891 (37) | 2385 (38) | ||
| del13q, n (% positive) | 686 (41) | 612 (46) | 428 (43) | 1807 (48) | 3533 (46) | |||
| del17p, n (% positive) | 351 (11) | 591 (8) | 423 (9) | 1651 (15) | 3016 (12) | |||
| gain9, n (% positive) | 454 (57) | 480 (60) | 351 (66) | 1285 (60) | ||||
| HR.FISH.A, n (% positive) | 354 (46) | 535 (48) | 368 (48) | 116 (100)‡ | 1022 (64) | 2395 (57) | ||
| HR.FISH.B/ISS, n (low/medium/high %) | 334 (60/22/18) | † | † | 516 (55/29/17)† | 850 (57/26/17) | |||
| . | HO65/HD4 . | MRC-IX . | TT2 . | TT3 . | APEX . | IFM-G . | Pooled . | |
|---|---|---|---|---|---|---|---|---|
| . | . | Intensive . | Nonintensive . | . | . | . | . | . |
| N | 827 | 701 | 491 | 351 | 238 | 264 | 1878 | 4750* |
| Age, median (IQR), y | 57 (51-61) | 58 (54-63) | 74 (70-77) | 57 (49-64) | 60 (53-66) | 61 (54-67) | 57 (51-61) | 57 (51-62) |
| Treatment, n | PAD (413) | CTD (351) | CTDa (257) | VTD (175) | VTD (238) | BOR (188) | VD (740) | BOR (1579)/ THAL (783) |
| Control, n | VAD (414) | CVAD (350) | MP (234) | VMD (176) | No controls | DEX (76) | VAD (1138) | BOR (1628)/ THAL (760) |
| High-dose alkylator | Yes | Yes | No | Yes | Yes | Yes | Yes | |
| EMC92, n (% positive) | † | 138 (17) | 109 (24) | 345 (19) | 238 (15) | 264 (16) | 1094 (18) | |
| UAMS17, n (% positive) | 327 (12) | 138 (9) | 109 (16) | † | 238 (14) | 264 (12) | 1076 (12) | |
| UAMS70, n (% positive) | 327 (9) | 138 (7) | 109 (10) | † | 238 (12) | 264 (8) | 1076 (9) | |
| UAMS80, n (% positive) | 327 (8) | 138 (8) | 109 (9) | 345 (9) | † | 264 (7) | 1183 (8) | |
| MRCIX6, n (% positive) | 327 (5) | † | † | 345 (7) | 238 (5) | 264 (3) | 1174 (5) | |
| IFM15, n (% positive) | 327 (25) | 138 (25) | 109 (28) | 345 (24) | 238 (24) | 1157 (25) | ||
| HM19, n (low/medium/high %) | 327 (43/49/8) | 138 (45/48/7) | 109 (39/53/8) | 345 (50/47/8) | 238 (47/47/7) | 264 (41/50/8) | 1420 (44/48/8) | |
| GPI50, n (low/medium/high %) | 327 (34/51/15) | 138 (52/41/7) | 109 (52/38/10) | 345 (63/31/7) | 238 (58/34/8) | 1159 (51/39/10) | ||
| ISS, n (1/2/3%) | 756 (38/37/25) | 636 (25/39/36) | 449 (13/41/45) | 351 (54/25/21) | 208 (50/28 21) | 202 (34/33/33) | 1475 (34/39/28) | 4074 (34/37/30) |
| t(4;14), n (% positive) | 492 (12) | 619 (12) | 434 (10) | 1635 (14) | 3180 (13) | |||
| t(11;14), n (% positive) | 437 (16) | 617 (15) | 434 (12) | 1488 (15) | ||||
| t(14;16), n (% positive) | 360 (2) | 612 (3) | 434 (3) | 456 (4) | 1862 (3) | |||
| t(14;20), n (% positive) | 255 (0) | 612 (2) | 429 (1) | 1296 (1) | ||||
| IgH split, n (% positive) | 372 (48) | 609 (44) | 429 (40) | 1410 (44) | ||||
| gain1q, n (% positive) | 344 (32) | 531 (37) | 371 (41) | 248 (47) | 891 (37) | 2385 (38) | ||
| del13q, n (% positive) | 686 (41) | 612 (46) | 428 (43) | 1807 (48) | 3533 (46) | |||
| del17p, n (% positive) | 351 (11) | 591 (8) | 423 (9) | 1651 (15) | 3016 (12) | |||
| gain9, n (% positive) | 454 (57) | 480 (60) | 351 (66) | 1285 (60) | ||||
| HR.FISH.A, n (% positive) | 354 (46) | 535 (48) | 368 (48) | 116 (100)‡ | 1022 (64) | 2395 (57) | ||
| HR.FISH.B/ISS, n (low/medium/high %) | 334 (60/22/18) | † | † | 516 (55/29/17)† | 850 (57/26/17) | |||
The numbers of patients per data set are given, with the number or percentage of positive patients according to the markers’ risk classification.
Intersection of patients with available data between datasets is shown in supplemental Figure 1.
Training set for these markers. Only the proportion and number that are not used for building the marker, if any, are shown.
The HR.FISH.A compound risk classification is based on a patient having either del17p, t(4;14), or gain of 1q. If only gain of 1q is known (in TT2 patients), these are the only patients classified with certainty as high-risk. The remaining patients cannot be classified because the status of t(4;14) and del17p are unknown. If the missing bias is strong enough (see Methods), that marker is excluded from the combination analyses.
BOR, bortezomib; CTD, cyclophosphamide, thalidomide, dexamethasone; CTDa, attenuated CTD; CVAD, cyclophosphamide, vincristine, doxorubicin, dexamethasone; IgH, immunoglobulin H; IQR, interquartile range; MP, melphalan, prednisone; THAL, thalidomide; PAD, bortezomib, doxorubicin, dexamethasone; VAD, vincristine, doxorubicin, dexamethasone; VD, vincristine, dexamethasone; VMD, bortezomib, melphalan, dexamethasone; VTD, bortezomib, thalidomide, dexamethasone.